primary studies - published, non RCT

Long-term evaluation of effectiveness for selected chest physiotherapy methods used in the treatment of cystic fibrosis.

Code: PM12004158 **Year:** 2001 **Date:** **Author:** Orlik T

Study design (if review, criteria of inclusion for studies)

Multicenter retrospective study

Participants

13 adults and adolescents with CFRD

Interventions

Tandem t:slim X2 pump with Control IQâ„¢ technology, a HCL system.

Outcome measures

14 days of continuous glucose monitor data were analyzed at baseline, 1 and 3 months after transition to the Tandem t:slim X2 pump with Control IQâ„¢ technology

Main results

Control IQ initiation was associated with a significant increase in % time in target range (70-180â€‰mg/dL), as well as decreases in average glucose, % time in hyperglycemic ranges (% time >180â€‰mg/dL, % time >250â€‰mg/dL), and glycemic variability (standard deviation, coefficient of variation). There was no significant change in % time in hypoglycemia ranges (% time

Authors' conclusions

This is the first study to report a beneficial effect of Food and Drug Administration (FDA)-approved HCL technology on glycemia in adults and adolescents with CFRD to date. Future studies are needed to understand the potential long-term glycemic benefits of HCL devices and to explore the impact of this technology on heath-related quality of life, pulmonary function, nutritional status, and mortality.

http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/055/CN-00404055/frame.html

See also

Medycyna Wieku Rozwojowego YR: 2001 VL: 5 DE: CCT NO: 3

Keywords

hybrid closed loop (HCL) technology; non pharmacological intervention - devices OR physiotherapy; Diabetes Mellitus; Pancreatic Diseases; Gastrointestinal Diseases;